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Background: The prevalence of drug resistant tuberculosis (TB) in Ethiopia in general, and Jimma area in particular,
is not well documented. We conducted a study at Jimma University specialized hospital in southwest Ethiopia
among new cases of smear positive TB patients to determine the pattern of resistance to first-line drugs.
Methods: A health institution based cross sectional study was conducted from November 2010 to September 2011.
Any newly diagnosed smear positive TB patient 18 years and above was included in the study. Demographic and
related data were collected by trained personnel using a pretested structured questionnaire. Mycobacterial drug
susceptibility testing (DST) to the first line drugs isoniazid (INH), rifampicin (RIF), ethambutol (EMB) and streptomycin
(STM) was performed on cultures using the indirect proportion method. M. tuberculosis complex (MTBC) was
identified with the Capilia TB-Neo test.
Results: 136 patients were enrolled in the study. Resistance to at least one drug was identified in 18.4%. The
highest prevalence of resistance to any drug was identified against INH (13.2%) followed by STM (8.1%). There was
no statistically significant difference in the proportion of any resistance by sex, age, HIV status and history of being
imprisoned. The highest mono resistance was observed against INH (7.4%). Mono resistance to streptomycin was
associated with HIV infection (crude OR 15.63, 95%CI: 1.31, 187). Multidrug-resistance TB (MDR-TB) was observed in
two patients (1.5%).
Conclusion: Resistance to at least one drug was 18.4% (INH-13.2% and STM-8.1%). STM resistance was associated
with HIV positivity. There was relatively low prevalence of MDR-TB yet INH resistance was common around Jimma.
The capacity of laboratories for TB culture and DST should be strengthened, in order to correctly manage TB
patients and avoid amplification of drug resistance.
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TB is the world’s leading curable cause of infectious dis-
eases mortality, with a disproportionate burden of the dis-
ease falling on low and middle income countries. In 2010,
there were an estimated 8.8 million incident cases of TB
globally. Most of the estimated number of cases occurred
in Asia (59%) and Africa (26%) [1]. While most TB cases
are in Asia, in Africa the incidence rates are highest,
driven by high rates of HIV and malnutrition [2].* Correspondence: gemeda.abebe@ju.edu.et
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reproduction in any medium, provided the orOne of the aims of ensuring effective management of TB
is to minimize the development of drug resistance, which
results from inadequate therapy. Surveillance of anti-TB
drug resistance is therefore an essential tool for monitoring
the effectiveness of TB control programs and improving
control efforts. The emergence of drug resistance in recent
years has highlighted the importance of an effective control
strategy for tuberculosis. The rapid spread of drug resist-
ance, multi-drug resistant TB (MDR-TB) and extensively
drug resistant TB (XDR-TB), both in new and in previously
treated cases, adds urgency to the need for decisive action
to develop and implement control measures [2].
Ethiopia is one of the high burden countries, reflected
both in its TB incidence and the estimated rates of MDRLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Abebe et al. BMC Research Notes 2012, 5:225 Page 2 of 6
http://www.biomedcentral.com/1756-0500/5/225TB. However, there has been no reliable estimate on ei-
ther general prevalence or drug resistance of TB. To
date a single TB drug resistance survey was conducted
back in 2005 [3]. The laboratory capacity in Ethiopia to
diagnose MDR TB is very limited. There was only one
public laboratory that became functional two years ago
that could perform both MTB culture and drug resist-
ance testing. As a result national estimates were based
on incomplete data that suffer from representativeness
since the reporting system is poorly developed, diagnos-
tic criteria are usually non-standardized and many MDR
cases go undetected [4].
WHO estimates for Ethiopia indicates that the rate of
MDR-TB is 1.6% for new cases and 12% for retreatment
cases [1]. Reports from different parts of Ethiopia sug-
gest that the rate of drug resistant TB is highly variable
across the country [5-9]. To date there is however no re-
port on anti-tuberculosis drug resistance from the south-
west part of Ethiopia in general and the Jimma area in
particular. The aim of the present study was to deter-
mine the susceptibility to STM, INH, RIF and EMB of
Mycobacterium tuberculosis complex strains isolated
from patients newly diagnosed with pulmonary tubercu-
losis at Jimma University Specialized hospital.
Methods
Study setting
The study was conducted at Jimma University Specia-
lized hospital, located in Jimma town, southwest Oro-
mia, Ethiopia, at a distance of 355 Km from the capital
city Addis Ababa. The total population of Jimma zone
according to the 2005 census report is 2,773,730, of
whom 1,382,460 (49.8%) were males. According to this
report 340,666 (12.3%) of the Jimma population live in
an urban environment. With an estimated area of
18,412.54 square kilometers, the population density was
151 people per square kilometer.
Study design and period
In this cross sectional study we enrolled all consenting
smear-positive new cases of TB patients aged≥ 18 years.
Three consecutive sputum samples (spot, early morning
and spot) were taken from each patient according the
Ethiopian National TB and Leprosy guidelines. Only the
samples smear positive for acid fast bacilli by Ziehl Neel-
sen smear microscopy were further processed by culture
(one per patient). Samples were stored at the Jimma Uni-
versity Mycobacteriology laboratory at 4°C and were cul-
tured within 48 hours. TB patients enrolled in the
study completed a questionnaire containing demographic
information, history of anti-TB treatment, history of con-
tact with chronic coughers, use of injectable drugs, history
of diabetes, alcohol usage and history of imprisonment.
The HIV status was collected from records. At JimmaUniversity specialized hospital voluntary counseling and
testing for HIV was routinely offered to all TB patients, as
recommended by WHO in countries with a generalized
HIV epidemic [10]. The study was conducted from No-
vember 2010 to September 2011.
Sample size
The number of new smear positive cases to be included
in this study was calculated according to the sampling
method described in "Guidelines for surveillance of drug
resistance in tuberculosis" developed by WHO/IUATLD
[11], using the following parameters: the number of
smear positive cases registered at Jimma University spe-
cialized hospital during 2008/2009 was 495, the resist-
ance to rifampicin in new TB cases from a previous
study in Ethiopia was 1.2% [5] and the degree of desired
precision was 1.5%. To compensate for expected losses
the calculated sample size was increased by 15%, result-
ing in a total sample size of 156 patients.
Sputum sample processing
Good quality specimens (inspected visually) with enough
volume (2.5-10 ml) were processed by the standard N-
acetyl L-cysteine (NALC)-NaOH method [12] and con-
centrated at 3000 × g for 20 minutes. The sediment was
reconstituted to 2.5 ml with phosphate buffer (pH 6.8)
to make the suspensions for the smears and cultures.
Culture and identification
One sputum sample per patient was cultured for the
presence of M. tuberculosis complex by use of either
Löwenstein-Jensen (LJ) slants (November 2010 to April
2011) or the BACTEC MGIT 960 system (Becton Dick-
inson Microbiology systems, Sparks, MD, USA) (May to
September 2011), according to the manufacturers
recommendations [13]. LJ slants were inoculated with
the sediment, incubated at 37°C and examined weekly
for growth. Cultures were considered negative when no
colonies were seen after 8 weeks incubation. In case of
MGIT 960, the MGIT tubes (7 ml) were inoculated with
the processed specimen, the tubes were incubated at 37
0 C in the BACTEC MGIT 960 instrument and were
monitored automatically every 60 minutes for increase
in fluorescence [13]. The cultures were tested until posi-
tive or for 6 weeks. The isolates from either LJ or MGIT
960 tubes were confirmed to be MTB complex by com-
bination of microscopic observation for serpentine cord
formation and testing with Capilia TB-Neo (Tauns La-
boratories, Inc, Shizuoka, Japan).
Drug susceptibility testing
All M. tuberculosis complex strains as determined by
cord formation and Capilia test were subjected to sus-
ceptibility testing to the first line anti-tuberculosis drugs













18-24 33 (62.3) 20(37.7) 2(3.8) 38(71.7) 13(24.5)
25-34 28 (54.9) 23 (45.1) 9(17.6) 30(58.8) 12(23.5)
35-44 7(41.2) 10(58.8) 1(5.9) 11(64.7) 5(29.4)
> = 45 10(66.7) 5(33.3) 1(6.7) 8(53.3) 6(40.0)
Total 78(57.4) 58(42.6) 13(9.6) 87(64.0) 36(26.5)
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960 tubes (May to September 2011). The indirect pro-
portion method on LJ media was performed at the fol-
lowing final drug concentrations: STM at 4 μg/ml, INH
at 0.2 μg/ml, RPM at 40 μg/ml and EMB at 2 μg/ml.
The slopes were incubated at 370 C and read daily for
one week for the possibility of contamination and
growth of fast growing mycobacteria, and then read at
28 days and at 42 days. Drug resistance was defined as
growth on a drug containing medium greater than or
equal to 1% of that recorded on the drug-free control
medium of the same experiment. DST using MGIT 960
followed standard procedures according to the manufac-
turer’s recommendation [13]. Final drug concentrations
were 1.0 μg/ml for STM, 0.1 μg/ml for INH, 1.0 μg/ml
for RMP and 5.0 μg/ml for EMB. The results were auto-
matically interpreted by the BACTEC MGIT 960 instru-
ment and reported as either susceptible or resistant.
Quality control and purity checks
The reference strain of M. tuberculosis H37Rv (ATCC
27294), which is susceptible to all standard anti-
tuberculosis drugs, was used in each batch of media pre-
pared with drugs. All bacterial suspensions used for DST
in MGIT 960 were checked for purity on blood agar and
sabouraud dextrose agar. In every DST step H37Rv
(ATCC 27294) was used as susceptible control.
Statistical analysis
Data were entered and analyzed by SPSS version 15.0
statistical software (SPSS Inc. Chicago, 2007). Descrip-
tive analysis was done to depict the socio-demographic
variables and proportion of drug resistant TB. Univariate
logistic regression test was used to evaluate the associ-
ation between drug resistance and socio-demographic
status, HIV infection and a history of imprisonment.
P value less than or equal to 0.05 was considered statis-
tically significant.
Ethical consideration
The study protocol was approved by the ethical review
committees of Jimma University, Ministry of Science
and Technology, Ethiopia and University of Antwerp,
Belgium. Written informed consent was obtained from
the study participants. The DST results were communi-
cated to the treating physicians. MDR-TB cases were re-
ferred to a specialized central MDR-TB clinic in Addis
Ababa to start treatment.
Results
During the study period at Jimma University specialized
hospital a total of 176 sputum smear positive TB
patients were registered of whom 156 new cases of spu-
tum smear positive TB patients were enrolled. Twentypatients were excluded based on previous history of
anti-TB treatment for more than one month. The 156
participants provided 468 sputum samples for micros-
copy. One hundred and fifty-six smear positive sputum
samples (one per patient) were cultured, which grew M.
tuberculosis in samples from 136 (87.2%) patients, while
cultures from 12(7.7%) patients were contaminated and
8 (5.1%) did not grow. Samples that were contaminated
or failed to grow were excluded from further analysis. Of
the 136 patients with viable isolates, the majority (57.4%)
were males. Thirteen (9.6%) were HIV seropositive, of
whom 5 were receiving antiretroviral therapy. The age of
the study subjects ranged from 18 to 64 years with me-
dian age of 26.0 (± 10.7) years (Table 1).
All the 136 isolates were identified as M. tuberculosis
complex. Among these, 111 (81.6%) were susceptible to
all the drugs tested, while 25 (18.4%) were resistant to at
least one drug. Resistance to more than one drug (ex-
cluding the combination of INH and RIF) was observed
in 6(4.4%) patient isolates (Table 2). When each drug
was considered separately, the highest rates of resistance
(single or in combination) were observed for INH
(13.2%) and STM (8.1%), followed by EMB (5.2%) and
RMP (2.2%). A total of 4 isolates (2.9%) were resistant to
two drugs only, 2 (1.5%) to three drugs only and 2(1.5%)
to four drugs. Highest mono resistance was observed
against INH (7.4%). Two (1.5%) MDR-TB strains (resist-
ant to both INH and RIF) were found.
Of the 13 HIV-infected patients, 3 had isolates resist-
ant to at least one of the four drugs but none of them
were MDR-TB. There was no statistically significant dif-
ference in the proportion of any resistance by sex, age,
HIV status and history of being imprisoned (Table 3)
with the exception of mono resistance to streptomycin,
which was associated with HIV infection (crude OR
15.63, 95%CI: 1.31, 187) (data not shown).Discussion
The re-emergence of TB as a global health problem
over the past two decades, together with the escalating
HIV epidemic and increasing anti-tuberculosis drug re-
sistance, represents a serious problem for TB control.
Table 2 Resistance pattern to first-line drugs (n = 136)
Resistance N(%) 95% CI
Any resistance 25(18.4) 12.8-25.7
Any STM 11(8.1) 4.6-13.9
Any INH 18(13.2) 8.5-20.0
Any RIF 3(2.2) 0.8-6.3






INH and RIF Resistances (MDR)
INH+ RIF only 0
INH+ RIF + EMB only 0
INH+ RIF + STM only 0
INH+ RIF + EMB+ STM only 2(1.5) 0.4-5.2
INH and other resistances
INH+ EMB only 1(0.7) 0.1-4.1
INH+ STM only 3(2.2) 0.8-6.3
INH+ EMB+ STM only 2(1.5) 0.4-5.2
RIF and other resistances
RIF + EMB only 0
RIF + STM only 0
RIF + EMB+ STM only 0
Poly Resistance 6(4.4) 2.0-9.3
RIF = Rifampicin,INH= Isoniazid, EMB = Ethambuthol, STM= Streptomycin,
MDR=multi-drug resistance, CI = Confidence interval.
Table 3 Univariable analysis for risk factors for any
anti-TB drug resistance
Characteristic Any resistance COR, 95% CI* P value
Yes n(%) No n(%)
Sex
Male 15(19.2) 63(80.8) 1 0.77
Female 10(17.2) 48(82.8) 1.14(0.47, 2.77)
Age
18-24 7(13.2) 46(86.8) 1 0.20
25-34 13(25.5) 38(74.5) 0.45(0.16, 1.23)
35-44 1(5.9) 16(94.1) 2.44(0.28, 21.35)
> = 45 4(26.7) 11(73.3) 0.42(0.10, 1.69)
HIV infection
Positive 4(23.1) 9(76.9) 1 0.25
Negative 15(14.9) 72(85.1) 2.13(0.58, 7.85)
History of being in prison
Yes 2(22.2) 7(77.8) 1 0.76
No 23(15.7) 104(85.0) 1.29(0.25, 6.63)
COR=Crude odds ratio, CI = confidence interval.
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ities, information on drug resistance from Ethiopia is
inadequate. We therefore performed a survey on pri-
mary anti-tuberculosis resistance, an indicator of the
NTP’s performance in controlling the spread of drug
resistance.
The overall observed primary resistance rate of 18.4%
is lower than the 26.9% rate reported in the Ethiopian
national survey performed in 2005 [3] and the study in
the eastern part of the country (32.5%) [8], but is close
to the rate reported in central (18.2%) [14] and North-
west part of the country (15.3%) [15]. Our study is single
institution based, thus cannot be compared with the
Ethiopian national survey. However, our data illustrates
the heterogeneity of TB drug resistance in Ethiopia.
Most of our study participants were from a rural area.
The study from the eastern part of Ethiopia was con-
ducted before 1997 when the DOTS program was not
fully implemented in the area. Our result is higher than
the sub regional study report from Zimbabwe (3.7%)
[16]. Compared with recent national surveys in other
regions of Africa our figures are higher than those from
Rwanda (10.4%), Tanzania (6.8%) and Botswana (10.4%),
but similar with the one from Côte d'Ivoire (23.8%) [3].
Most frequent resistance in our study was against INH
(13.2%) followed by STM (8.1%). Strains that were resist-
ant to only one drug were mainly resistant to INH
(7.4%) or STM (2.9%). The lowest resistance was against
RIF (2.2%). Other studies from the region have reported
similar findings [5,15,17,18]. This high INH resistance
has implications for both treatment and prevention of
TB. First, INH is an integral component of standard
DOTS regimen. Secondly, in high INH resistance set-
tings the effectiveness of INH preventive therapy may be
compromised. Observations from different studies indi-
cate that resistance to both INH and STM increases the
risk of selection for MDR-TB during the intensive phase
of treatment [17,19]. In some strains of M. tuberculosis
mono resistance to STM was related to development of
MDR [20]. Since the population structure of the M. tu-
berculosis complex in Ethiopia is not well documented,
molecular characterization of strains from the region is
recommended.
The clinical management of TB is complicated when
isolates are resistant to both INH and RIF (MDR). There
are few drugs available to treat MDR-TB. It takes longer
(up to 24 months) to treat such cases and the drugs are
more toxic. The treatment success rate is generally poor
compared with drug susceptible TB [21-23]. The pro-
portion of MDR-TB in our study is consistent with the
national survey findings [3], WHO estimate for Ethiopia
in 2010 [1] and the recent report from Addis Ababa [5]
but higher than the report from northwest part of Ethi-
opia [15]. The two MDR-TB strains in our study were
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strain was isolated from HIV seropositive patients. The
heterogeneous nature of MDR-TB in Ethiopia necessi-
tates regular surveys. To this effect, the laboratory cap-
acity strengthening should be promoted so that
systematic follow-up of trends could be possible
through regular testing of retreatment cases. Currently,
the laboratory capacity in the country is inadequate.
WHO recommends 1 TB culture facility with DST for
5 million people. Currently in Ethiopia there is only
one such public facility per 50 million people [1].
Our study was not without pitfall. The major limita-
tion was that we used only Capilia and serpentine cord
formation to identify Mycobacterium tuberculosis com-
plex. These two methods are not confirmatory. Both
false positive and false negative results do occur with
Capilia tests [24,25].
Conclusion
Resistance to at least one drug was 18.4% (INH-13.2%
and STM-8.1%). STM resistance was associated with
HIV positivity. There was a relatively low MDR-TB but
high INH resistance rate around Jimma. The capacity
strengthening of laboratories for TB culture and DST
should be promoted.
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